GSK therapy for multiple myeloma receives breakthrough therapy designation

The Food and Drug Administration (FDA) has granted breakthrough therapy designation to GlaxoSmithKline (GSK) for its investigational B-cell mutation agent (BCMA) monoclonal antibody-drug conjugate, GSK2857916, for relapsed and refractory multiple myeloma. Expand This investigational therapy has also been granted PRIME designation from the European Medicines Agency (EMA) back in October for the treatment of relapsed […]